Shattuck Labs Q2 net loss widens as R&D spending rises

Shattuck Labs

11/08/2026 11:25

Overview
Biotechnology firm's Q2 net loss widened as R&D expenses increased and revenue remained nil
Company ended Q2 with $208.3 mln in cash and investments, funding expected into 2029
Shattuck completed $86.2 mln public offering and $57.1 mln in warrant exercises in Q2

Outlook
Company expects to initiate Phase 2b trial of SL-325 in Crohn's disease in Q3 2026
Primary endpoint data from SL-325 Phase 2b trial expected in first half of 2028
Company expects current cash and investments to fund operations into 2029

Result Drivers
R&D SPENDING - Higher research and development expenses as company advances clinical pipeline
CLINICAL PROGRESS - Phase 1 trial for SL-325 showed favorable safety and immunogenicity profiles and durable DR3 blockade
PIPELINE ADVANCEMENT - Company announced progress on SL-846 bispecific antibody, with preclinical and clinical data expected

Company press release: ID:nGNX1lYdXb

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$15.15 mln
 
Q2 Income From Operations
 
-$16.16 mln
 
Q2 Loss Per Basic Share
 
$0.12
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Shattuck Labs Inc is $16.50, about 131.1% above its August 10 closing price of $7.14

Reuters Recommended Reads
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)